ENSC Share Price Performance
Recent ENSC News & Updates
No updates
Ensysce Biosciences, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.87
- Gross Margin
- -33.77%
- Net Profit Margin
- -109.51%
- Debt/Equity Ratio
- 9.5%
Ensysce Biosciences, Inc. Competitors
About ENSC
- Founded
- 2003
- Employees
- 8
- CEO
- WebsiteView website
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
U.S. Market Performance
- 7 Days: -0.6%
- 3 Months: 11.8%
- 1 Year: 16.8%
- Year to Date: 7.5%
In the last week, the market has been flat, with a notable exception in the Healthcare sector dropping 4.2%. As for the longer term, the market has risen 17% in the past 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading